Researchers at Stanford have developed genetically encoded STING agonists that enable controlled activation of the STING pathway from within engineered cells.
Stanford researchers have developed the Broadly Usable Multi-Pass Engineered Receptor (BUMPER) architecture, a novel protein engineering platform for assembling stable, multifunctional cell surface receptors.
Stanford researchers have developed a novel mutant IL-9 receptor (IL9R) that significantly enhances the in vivo engraftment, expansion, and anti-tumor activity of adoptively transferred T cells.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Stanford Scientists have developed an innovative approach that enhances the antitumor efficacy of CAR T cells by overexpressing Adenosine Deaminase 1 (ADA), an enzyme responsible for metabolizing adenosine into inosine, to attenuate the immunosuppressive tumor microenvironment
A major barrier in CAR-T cell therapies has been T cell exhaustion, which affects the durability and effectiveness of treatments, particularly for solid tumors.
Stanford researchers developed a technology that efficiently identifies combinations of genetic interventions with lasting, effective therapeutic functions by constructing genetic perturbation libraries containing the desired combination of phenotypes extracted from each cell.